NZ597580A - Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof - Google Patents

Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof

Info

Publication number
NZ597580A
NZ597580A NZ597580A NZ59758010A NZ597580A NZ 597580 A NZ597580 A NZ 597580A NZ 597580 A NZ597580 A NZ 597580A NZ 59758010 A NZ59758010 A NZ 59758010A NZ 597580 A NZ597580 A NZ 597580A
Authority
NZ
New Zealand
Prior art keywords
hsa
variant
serum albumin
human serum
beta
Prior art date
Application number
NZ597580A
Other languages
English (en)
Inventor
Wen-Mei Fu
Woei-Jer Chuang
Original Assignee
Univ Nat Taiwan
Univ Nat Cheng Kung
Dcb Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Taiwan, Univ Nat Cheng Kung, Dcb Usa Llc filed Critical Univ Nat Taiwan
Publication of NZ597580A publication Critical patent/NZ597580A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ597580A 2009-07-20 2010-07-19 Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof NZ597580A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22694509P 2009-07-20 2009-07-20
PCT/US2010/042423 WO2011011315A1 (en) 2009-07-20 2010-07-19 POLYPEPTIDES SELECTIVE FOR AV β3 INTEGRIN CONJUGATED WITH A VARIANT OF HUMAN SERUM ALBUMIN (HSA) AND PHARMACEUTICAL USES THEREOF

Publications (1)

Publication Number Publication Date
NZ597580A true NZ597580A (en) 2013-11-29

Family

ID=43465728

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597580A NZ597580A (en) 2009-07-20 2010-07-19 Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof

Country Status (14)

Country Link
US (1) US20110015130A1 (https=)
EP (1) EP2456454A4 (https=)
JP (1) JP2012533631A (https=)
KR (1) KR20120097481A (https=)
CN (1) CN102470156A (https=)
AR (1) AR077764A1 (https=)
AU (1) AU2010276453A1 (https=)
CA (1) CA2768360A1 (https=)
IL (1) IL217424A0 (https=)
MX (1) MX2012000895A (https=)
NZ (1) NZ597580A (https=)
RU (1) RU2547592C2 (https=)
TW (1) TWI557224B (https=)
WO (1) WO2011011315A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
US8357652B2 (en) * 2009-11-20 2013-01-22 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
US9044436B2 (en) * 2009-12-23 2015-06-02 National Cheng Kung University Compositions and methods for the treatment of angiogenesis-related eye diseases
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
RU2650784C2 (ru) 2011-05-05 2018-04-17 Альбумедикс А/С Варианты альбумина
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US10508137B2 (en) * 2014-08-22 2019-12-17 National Cheng Kung Univeristy Disintegrin variants and pharmaceutical uses thereof
ES2797901T3 (es) * 2015-06-28 2020-12-04 Allgenesis Biotherapeutics Inc Proteínas de fusión para la inhibición de angiogénesis
BR102016018074A2 (pt) * 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EP3870211B1 (en) 2018-10-22 2025-01-08 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
CN117321208A (zh) * 2021-03-16 2023-12-29 Km生物医药股份公司 经修饰的人血清白蛋白-硫氧还蛋白融合体
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2026022392A1 (en) * 2024-07-26 2026-01-29 Ospedale San Raffaele S.R.L. Peptide and conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU5939890A (en) * 1989-06-07 1991-01-07 Genentech Inc. Platelet aggregation inhibitors and related molecules
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
WO2003042354A2 (en) * 2001-09-04 2003-05-22 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
CA2465891C (en) * 2001-11-05 2012-05-15 Board Of Regents, The University Of Texas System Recombinant antibodies for the detection and neutralization of anthrax toxin
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
CA2489186C (en) * 2002-06-07 2013-01-15 Wisconsin Alumni Research Foundation Chemical synthesis of reagents for peptide coupling
WO2005090400A1 (en) * 2004-03-18 2005-09-29 The University Court Of The University Of Glasgow Immunosuppressive cytokine
WO2008056961A1 (en) * 2006-11-10 2008-05-15 Boryung Pharmaceutical Co., Ltd A novel fusion protein, cell lines expressing the same and preparation method thereof
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
US9044436B2 (en) * 2009-12-23 2015-06-02 National Cheng Kung University Compositions and methods for the treatment of angiogenesis-related eye diseases

Also Published As

Publication number Publication date
TW201107471A (en) 2011-03-01
AR077764A1 (es) 2011-09-21
CA2768360A1 (en) 2011-01-27
WO2011011315A1 (en) 2011-01-27
EP2456454A4 (en) 2013-03-20
CN102470156A (zh) 2012-05-23
JP2012533631A (ja) 2012-12-27
RU2012105915A (ru) 2013-08-27
MX2012000895A (es) 2012-06-01
IL217424A0 (en) 2012-02-29
EP2456454A1 (en) 2012-05-30
US20110015130A1 (en) 2011-01-20
RU2547592C2 (ru) 2015-04-10
TWI557224B (zh) 2016-11-11
AU2010276453A1 (en) 2012-02-09
KR20120097481A (ko) 2012-09-04

Similar Documents

Publication Publication Date Title
NZ597580A (en) Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
MY151184A (en) A polypeptide complex comprising non-peptidyl polymer having three functional ends
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
NZ707439A (en) Modified factor ix polypeptides and uses thereof
NZ600731A (en) Oxyntomodulin peptide analogue
NZ603445A (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
UA103215C2 (uk) Поліпептид з ксиланазною активністю
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
ATE533785T1 (de) Peptidfragmente zur induzierung der synthese extrazellulärer matrixproteine
PE20130523A1 (es) Nuevos peptidos y metodos para su preparacion y uso
WO2009058957A3 (en) Intranasal administration of active agents to the central nervous system
BR112014019901A8 (pt) Proteínas de fator viii recombinante
IL216861A (en) Nucleic Acids Encoded by Activin Binding Polypeptides, gdf8 or gdf11
IN2012DN02981A (https=)
NZ607069A (en) Modified relaxin polypeptides and their uses
IN2012DN02764A (https=)
NZ600363A (en) Modified porcine somatotropin polypeptides and their uses
NZ602702A (en) Modified fgf-21 polypeptides and their uses
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
NZ596501A (en) Casb7439 constructs
NZ594268A (en) Grass peptides for vaccine
NZ590469A (en) Treatment of rheumatoid arthritis with human beta defensins (1-4)
NZ603942A (en) Vitronectin:keratinocyte growth factor chimeras
ZA200901342B (en) Cytokine derivatives

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: NATIONAL TAIWAN UNIVERSITY, TW

Effective date: 20131205

Owner name: NATIONAL CHENG KUNG UNIVERSITY, TW

Effective date: 20131205

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 JUL 2017 BY COMPUTER PACKAGES INC

Effective date: 20140729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JUL 2018 BY CPA GLOBAL

Effective date: 20170718

LAPS Patent lapsed